
    
      Global Phase 3, open label long term extension safety study designed to obtain additional
      safety data for tafamidis meglumine 20 mg and 80 mg (or tafamidis 61 mg where available), and
      to continue to provide enrolled subjects with tafamidis for up to 60 months, or until subject
      has access to tafamidis for ATTR CM via prescription, whichever occurs first.
    
  